Target family: Adrenoceptors (type: gpcr)
Target: &beta;<sub>1</sub>-adrenoceptor

Ligand: 7-methylcyanopindolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 10.399999618530273 pKd
Reference (Journal): Pharmacological Analysis and Structure Determination of 7-Methylcyanopindolol-Bound &#x3b2;1-Adrenergic Receptor.
Published in: Mol Pharmacol

Ligand: abediterol (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 7.440000057220459 pIC50
Reference (Journal): Pharmacological characterization of abediterol, a novel inhaled β(2)-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models.
Published in: J Pharmacol Exp Ther

Ligand: acebutolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1984)
Primary target: yes
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Published in: Br J Pharmacol

Ligand: acebutolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1984)
Primary target: yes
Median affinity:  pKi
Reference (Webpage): National Toxicology Program: Dept of Health and Human Services.

Ligand: (-)-adrenaline (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (no history prior to 1951)
Primary target: no
Median affinity: 7.599999904632568 pEC50
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: (-)-adrenaline (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (no history prior to 1951)
Primary target: no
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: (-)-adrenaline (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (no history prior to 1951)
Primary target: no
Median affinity:  pKi
Reference (Journal): Structural basis of beta-adrenergic receptor subtype specificity studied with chimeric beta 1/beta 2-adrenergic receptors.
Published in: Proc Natl Acad Sci USA

Ligand: (-)-adrenaline (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (no history prior to 1951)
Primary target: no
Median affinity:  pKi
Reference (Journal): Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: atenolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1981)
Primary target: no
Median affinity: 6.800000190734863 pA2
Reference (Journal): Pharmacological properties of &#x3b2;-adrenoceptors mediating rat superior mesenteric artery relaxation and the effects of chemical sympathetic denervation.
Published in: Life Sci

Ligand: atenolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1981)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Binding of (-)-[3H]-CGP12177 at two sites in recombinant human beta 1-adrenoceptors and interaction with beta-blockers.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: atenolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1981)
Primary target: yes
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Published in: Br J Pharmacol

Ligand: atenolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1981)
Primary target: yes
Median affinity:  pKi
Reference (Journal): LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors.
Published in: Eur J Pharmacol

Ligand: betaxolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1985)
Primary target: yes
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Published in: Br J Pharmacol

Ligand: betaxolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1985)
Primary target: yes
Median affinity:  pKi
Reference (Journal): LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors.
Published in: Eur J Pharmacol

Ligand: betaxolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1985)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Levobetaxolol (Betaxon) and other beta-adrenergic antagonists: preclinical pharmacology, IOP-lowering activity and sites of action in human eyes.
Published in: J Ocul Pharmacol Ther

Ligand: BI-167107 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 9.220000267028809 pEC50
Reference (Journal): Binding pathway determines norepinephrine selectivity for the human &#x3b2;<sub>1</sub>AR over &#x3b2;<sub>2</sub>AR.
Published in: Cell Res

Ligand: BI-167107 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 9.220000267028809 pEC50
Reference (Journal): Use of 5-hydroxy-4H-benzo[1,4]oxazin-3-ones as beta2-adrenoceptor agonists.
Published in: Bioorg Med Chem Lett

Ligand: bisoprolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1992)
Primary target: no
Median affinity: 7.800000190734863 pKi
Reference (Journal): Novel selective &#x3b2;<sub>1</sub>-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease.
Published in: FASEB J

Ligand: BRL 37344 (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity: 6.5 pEC50
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: BRL 37344 (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity: 5.199999809265137 pKi
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: bucindolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.300000190734863 pKi
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: bunolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1985)
Primary target: no
Median affinity: 8.399999618530273 pKi
Reference (Webpage): National Toxicology Program: Dept of Health and Human Services.

Ligand: bunolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1985)
Primary target: yes
Median affinity: 8.399999618530273 pKi
Reference (Webpage): National Toxicology Program: Dept of Health and Human Services.

Ligand: bupranolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Primary target: yes
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Published in: Br J Pharmacol

Ligand: bupranolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Primary target: yes
Median affinity:  pKi
Reference (Journal): LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors.
Published in: Eur J Pharmacol

Ligand: bupranolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Primary target: yes
Median affinity:  pKi
Reference (Journal): Potent and selective human beta(3)-adrenergic receptor antagonists.
Published in: J Pharmacol Exp Ther

Ligand: bupranolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Primary target: no
Median affinity: 9 pA2
Reference (Journal): Pharmacological properties of &#x3b2;-adrenoceptors mediating rat superior mesenteric artery relaxation and the effects of chemical sympathetic denervation.
Published in: Life Sci

Ligand: carazolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Primary target: no
Median affinity:  pKd
Reference (Journal): Pharmacological Analysis and Structure Determination of 7-Methylcyanopindolol-Bound &#x3b2;1-Adrenergic Receptor.
Published in: Mol Pharmacol

Ligand: carazolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Primary target: no
Median affinity:  pKd
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: carvedilol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1995)
Primary target: yes
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Published in: Br J Pharmacol

Ligand: carvedilol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1995)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Potent and selective human beta(3)-adrenergic receptor antagonists.
Published in: J Pharmacol Exp Ther

Ligand: CGP 12177 (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity: 9.399999618530273 pKi
Reference (Journal): LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors.
Published in: Eur J Pharmacol

Ligand: CGP 12177 (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity: 9.399999618530273 pKi
Reference (Journal): The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Published in: Br J Pharmacol

Ligand: CGP 12177 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Use of a new proximity assay (NanoBRET) to investigate the ligand-binding characteristics of three fluorescent ligands to the human <i>&#x3b2;</i><sub>1</sub>-adrenoceptor expressed in HEK-293 cells.
Published in: Pharmacol Res Perspect

Ligand: CGP 12177 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Binding of (-)-[3H]-CGP12177 at two sites in recombinant human beta 1-adrenoceptors and interaction with beta-blockers.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: CGP 12177 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Published in: Br J Pharmacol

Ligand: CGP 12177 (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity: 9.399999618530273 pKi
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: CGP 20712A (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Published in: Br J Pharmacol

Ligand: CGP 20712A (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors.
Published in: Eur J Pharmacol

Ligand: CGP 20712A (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Use of a new proximity assay (NanoBRET) to investigate the ligand-binding characteristics of three fluorescent ligands to the human <i>&#x3b2;</i><sub>1</sub>-adrenoceptor expressed in HEK-293 cells.
Published in: Pharmacol Res Perspect

Ligand: CGP 20712A (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Pharmacological Analysis and Structure Determination of 7-Methylcyanopindolol-Bound &#x3b2;1-Adrenergic Receptor.
Published in: Mol Pharmacol

Ligand: CGP 20712A (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Potent and selective human beta(3)-adrenergic receptor antagonists.
Published in: J Pharmacol Exp Ther

Ligand: cicloprolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 8 pKi
Reference (Journal): LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors.
Published in: Eur J Pharmacol

Ligand: cimaterol (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 6.599999904632568 pKi
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: cimaterol (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 8.399999618530273 pEC50
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: clenbuterol (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 9.199999809265137 pEC50
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: clenbuterol (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: clenbuterol (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Salmeterol's extreme &#x3b2;2 selectivity is due to residues in both extracellular loops and transmembrane domains.
Published in: Mol Pharmacol

Ligand: cyanopindolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKd
Reference (Journal): Pharmacological Analysis and Structure Determination of 7-Methylcyanopindolol-Bound &#x3b2;1-Adrenergic Receptor.
Published in: Mol Pharmacol

Ligand: cyanopindolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKd
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: denopamine (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: denopamine (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity: 7.699999809265137 pEC50
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: denopamine (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Binding pockets of the beta(1)- and beta(2)-adrenergic receptors for subtype-selective agonists.
Published in: Mol Pharmacol

Ligand: denopamine (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Cellular characterization of the pharmacological selectivity and tachyphylactic properties of denopamine for the human beta adrenergic receptors.
Published in: J Pharmacol Exp Ther

Ligand: dobutamine (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1978)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Binding pockets of the beta(1)- and beta(2)-adrenergic receptors for subtype-selective agonists.
Published in: Mol Pharmacol

Ligand: dobutamine (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1978)
Primary target: yes
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: dobutamine (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1978)
Primary target: no
Median affinity: 6.800000190734863 pEC50
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: esmolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1986)
Primary target: yes
Median affinity:  pKi
Reference (Webpage): National Toxicology Program: Dept of Health and Human Services.

Ligand: esmolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1986)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Comparison of the &#x3b2;-Adrenergic Receptor Antagonists Landiolol and Esmolol: Receptor Selectivity, Partial Agonism, and Pharmacochaperoning Actions.
Published in: J Pharmacol Exp Ther

Ligand: fenoterol (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Primary target: no
Median affinity: 5 pKi
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: fenoterol (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Primary target: no
Median affinity: 7.5 pEC50
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: formoterol (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (2001)
Primary target: no
Median affinity: 8.300000190734863 pEC50
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: formoterol (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (2001)
Primary target: no
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: formoterol (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (2001)
Primary target: no
Median affinity:  pKi
Reference (Journal): A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of beta2-adrenoceptor agonists as inhaled long-acting bronchodilators.
Published in: Bioorg Med Chem Lett

Ligand: H87/07 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 7 pKi
Reference (Journal): LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors.
Published in: Eur J Pharmacol

Ligand: ICI-89406 (Synthetic organic)
Interaction type: Antagonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity: 8.800000190734863 pKi
Reference (Journal): Synthesis and in vitro and in vivo characterization of highly &#x3b2;1-selective &#x3b2;-adrenoceptor partial agonists.
Published in: J Med Chem

Ligand: indacaterol (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: EMA (2009), FDA (2011)
Primary target: no
Median affinity: 6.699999809265137 pKi
Reference (Journal): An investigation into the structure-activity relationships associated with the systematic modification of the β(2)-adrenoceptor agonist indacaterol.
Published in: Bioorg Med Chem Lett

Ligand: isoprenaline (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Primary target: yes
Median affinity:  pKi
Reference (Journal): Molecular characterization of pharmacological properties of T-0509 for beta-adrenoceptors.
Published in: Eur J Pharmacol

Ligand: isoprenaline (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Primary target: yes
Median affinity:  pKi
Reference (Journal): Structural basis of beta-adrenergic receptor subtype specificity studied with chimeric beta 1/beta 2-adrenergic receptors.
Published in: Proc Natl Acad Sci USA

Ligand: isoprenaline (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Primary target: no
Median affinity: 8.600000381469727 pEC50
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: isoprenaline (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Primary target: yes
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: labetalol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1984)
Primary target: yes
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Published in: Br J Pharmacol

Ligand: labetalol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1984)
Primary target: yes
Median affinity:  pKi
Reference (Webpage): National Toxicology Program: Dept of Health and Human Services.

Ligand: labetalol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1984)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Agonist and inverse agonist actions of beta-blockers at the human beta 2-adrenoceptor provide evidence for agonist-directed signaling.
Published in: Mol Pharmacol

Ligand: landiolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: Japan and some European countries.
Primary target: no
Median affinity: 7 pKi
Reference (Journal): Comparison of the &#x3b2;-Adrenergic Receptor Antagonists Landiolol and Esmolol: Receptor Selectivity, Partial Agonism, and Pharmacochaperoning Actions.
Published in: J Pharmacol Exp Ther

Ligand: levosalbutamol (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (prior to 1999)
Primary target: no
Median affinity: 4.699999809265137 pKi
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: levosalbutamol (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (prior to 1999)
Primary target: no
Median affinity: 6.199999809265137 pEC50
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: LK 204-545 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Novel selective &#x3b2;<sub>1</sub>-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease.
Published in: FASEB J

Ligand: LK 204-545 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors.
Published in: Eur J Pharmacol

Ligand: metoprolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1978)
Primary target: yes
Median affinity:  pKi
Reference (Journal): LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors.
Published in: Eur J Pharmacol

Ligand: metoprolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1978)
Primary target: yes
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Published in: Br J Pharmacol

Ligand: metoprolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1978)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Potent and selective human beta(3)-adrenergic receptor antagonists.
Published in: J Pharmacol Exp Ther

Ligand: metoprolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1978)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Agonist and inverse agonist actions of beta-blockers at the human beta 2-adrenoceptor provide evidence for agonist-directed signaling.
Published in: Mol Pharmacol

Ligand: metoprolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1978)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: mirabegron (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA and EMA (2012)
Primary target: no
Median affinity:  pEC50
Reference (Journal): Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function.
Published in: J Pharmacol Exp Ther

Ligand: mirabegron (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA and EMA (2012)
Primary target: no
Median affinity:  pEC50
Reference (Journal): The metabolic effects of mirabegron are mediated primarily by &#x3b2;<sub>3</sub> -adrenoceptors.
Published in: Pharmacol Res Perspect

Ligand: nadolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1979)
Primary target: yes
Median affinity: 6.900000095367432 pKi
Reference (Journal): Potent and selective human beta(3)-adrenergic receptor antagonists.
Published in: J Pharmacol Exp Ther

Ligand: NDD-713 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Novel selective &#x3b2;<sub>1</sub>-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease.
Published in: FASEB J

Ligand: NDD-713 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.100000381469727 pKd
Reference (Journal): Novel selective &#x3b2;<sub>1</sub>-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease.
Published in: FASEB J

Ligand: NDD-825 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Novel selective &#x3b2;<sub>1</sub>-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease.
Published in: FASEB J

Ligand: NDD-825 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.399999618530273 pKd
Reference (Journal): Novel selective &#x3b2;<sub>1</sub>-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease.
Published in: FASEB J

Ligand: nebivolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (2007)
Primary target: no
Median affinity: 9.100000381469727 pKi
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: nebivolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (2007)
Primary target: no
Median affinity:  pIC50
Reference (Journal): The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various beta-adrenergic blockers.
Published in: Mol Pharmacol

Ligand: NIHP (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 7.1 pKi
Reference (Journal): LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors.
Published in: Eur J Pharmacol

Ligand: NIP (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 8.4 pKi
Reference (Journal): LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors.
Published in: Eur J Pharmacol

Ligand: (-)-noradrenaline (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1950)
Primary target: no
Median affinity: 7.900000095367432 pEC50
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: (-)-noradrenaline (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1950)
Primary target: no
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: (-)-noradrenaline (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1950)
Primary target: no
Median affinity:  pKi
Reference (Journal): Structural basis of beta-adrenergic receptor subtype specificity studied with chimeric beta 1/beta 2-adrenergic receptors.
Published in: Proc Natl Acad Sci USA

Ligand: (-)-noradrenaline (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1950)
Primary target: no
Median affinity:  pKi
Reference (Journal): Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: noradrenaline (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6 pKi
Reference (Journal): Structural basis of beta-adrenergic receptor subtype specificity studied with chimeric beta 1/beta 2-adrenergic receptors.
Published in: Proc Natl Acad Sci USA

Ligand: pindolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1982)
Primary target: no
Median affinity:  pKi
Reference (Journal): Agonist and inverse agonist actions of beta-blockers at the human beta 2-adrenoceptor provide evidence for agonist-directed signaling.
Published in: Mol Pharmacol

Ligand: pindolol (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1982)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Indoloxypropanolamine analogues as 5-HT(1A) receptor antagonists.
Published in: Bioorg Med Chem Lett

Ligand: pindolol (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1982)
Primary target: yes
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: pindolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1982)
Primary target: no
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: pindolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1982)
Primary target: no
Median affinity:  pKi
Reference (Journal): Binding of (-)-[3H]-CGP12177 at two sites in recombinant human beta 1-adrenoceptors and interaction with beta-blockers.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: (±)-adrenaline (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6 pKi
Reference (Journal): Structural basis of beta-adrenergic receptor subtype specificity studied with chimeric beta 1/beta 2-adrenergic receptors.
Published in: Proc Natl Acad Sci USA

Ligand: practolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Primary target: yes
Median affinity:  pKi
Reference (Journal): LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors.
Published in: Eur J Pharmacol

Ligand: practolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Primary target: yes
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Published in: Br J Pharmacol

Ligand: prenalterol (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity: 6.599999904632568 pKi
Reference (Journal): Binding pockets of the beta(1)- and beta(2)-adrenergic receptors for subtype-selective agonists.
Published in: Mol Pharmacol

Ligand: prenalterol (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity: 6.599999904632568 pKi
Reference (Journal): Beta 1- and beta 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium.
Published in: Mol Pharmacol

Ligand: propafenone (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1989)
Primary target: yes
Median affinity: 6.699999809265137 pKi
Reference (Webpage): National Toxicology Program: Dept of Health and Human Services.

Ligand: (-)-propranolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: yes
Median affinity:  pKi
Reference (Journal): Use of a new proximity assay (NanoBRET) to investigate the ligand-binding characteristics of three fluorescent ligands to the human <i>&#x3b2;</i><sub>1</sub>-adrenoceptor expressed in HEK-293 cells.
Published in: Pharmacol Res Perspect

Ligand: (-)-propranolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: yes
Median affinity:  pKi
Reference (Journal): Binding of (-)-[3H]-CGP12177 at two sites in recombinant human beta 1-adrenoceptors and interaction with beta-blockers.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: (-)-propranolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: yes
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Published in: Br J Pharmacol

Ligand: (-)-propranolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: yes
Median affinity:  pKi
Reference (Journal): LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors.
Published in: Eur J Pharmacol

Ligand: (-)-Ro 363 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 8 pKi
Reference (Journal): Effects of (-)-RO363 at human atrial beta-adrenoceptor subtypes, the human cloned beta 3-adrenoceptor and rodent intestinal beta 3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: solabegron (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 5.400000095367432 pEC50
Reference (Journal): Biarylaniline phenethanolamines as potent and selective beta3 adrenergic receptor agonists.
Published in: J Med Chem

Ligand: sotalol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1992)
Primary target: yes
Median affinity:  pKi
Reference (Webpage): National Toxicology Program: Dept of Health and Human Services.

Ligand: sotalol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1992)
Primary target: yes
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Published in: Br J Pharmacol

Ligand: SR59230A (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: SR59230A (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Published in: Br J Pharmacol

Ligand: SR59230A (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Potent and selective human beta(3)-adrenergic receptor antagonists.
Published in: J Pharmacol Exp Ther

Ligand: [125I]ICYP (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKd
Reference (Journal): Molecular characterization of pharmacological properties of T-0509 for beta-adrenoceptors.
Published in: Eur J Pharmacol

Ligand: [125I]ICYP (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKd
Reference (Journal): Binding pockets of the beta(1)- and beta(2)-adrenergic receptors for subtype-selective agonists.
Published in: Mol Pharmacol

Ligand: [125I]ICYP (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKd
Reference (Journal): Markedly reduced effects of (-)-isoprenaline but not of (-)-CGP12177 and unchanged affinity of beta-blockers at Gly389-beta1-adrenoceptors compared to Arg389-beta1-adrenoceptors.
Published in: Br J Pharmacol

Ligand: [125I]ICYP (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKd
Reference (Journal): LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors.
Published in: Eur J Pharmacol

Ligand: [3H](-)CGP 12177 (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity:  pKd
Reference (Journal): Binding of (-)-[3H]-CGP12177 at two sites in recombinant human beta 1-adrenoceptors and interaction with beta-blockers.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: [3H](-)CGP 12177 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKd
Reference (Journal): Binding of (-)-[3H]-CGP12177 at two sites in recombinant human beta 1-adrenoceptors and interaction with beta-blockers.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: [3H](-)CGP 12177 (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity:  pKd
Reference (Journal): The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Published in: Br J Pharmacol

Ligand: [3H](-)CGP 12177 (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity:  pKd
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: [3H](-)CGP 12177 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKd
Reference (Journal): The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Published in: Br J Pharmacol

Ligand: [3H](-)CGP 12177 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKd
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: T-0509 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.6 pKi
Reference (Journal): Molecular characterization of pharmacological properties of T-0509 for beta-adrenoceptors.
Published in: Eur J Pharmacol

Ligand: terbutaline (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1974)
Primary target: no
Median affinity: 5.800000190734863 pEC50
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: terbutaline (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1974)
Primary target: no
Median affinity: 3.9000000953674316 pKi
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: timolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1981)
Primary target: no
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Published in: Br J Pharmacol

Ligand: timolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1981)
Primary target: no
Median affinity:  pKi
Reference (Journal): Binding of (-)-[3H]-CGP12177 at two sites in recombinant human beta 1-adrenoceptors and interaction with beta-blockers.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: timolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1981)
Primary target: no
Median affinity:  pKi
Reference (Journal): Agonist and inverse agonist actions of beta-blockers at the human beta 2-adrenoceptor provide evidence for agonist-directed signaling.
Published in: Mol Pharmacol

Ligand: xamoterol (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Binding pockets of the beta(1)- and beta(2)-adrenergic receptors for subtype-selective agonists.
Published in: Mol Pharmacol

Ligand: xamoterol (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Published in: Br J Pharmacol